Expression of matrix metalloproteinases and their tissue inhibitors in the serum and cerebrospinal fluid of patients with meningitis  by Tsai, H.‐C. et al.
Expression of matrix metalloproteinases
and their tissue inhibitors in the serum
and cerebrospinal fluid of patients with
meningitis
H.-C. Tsai1,2, M.-H. Shi1,2, S. S.-J. Lee1,2, S.-R. Wann1,2,
M.-H. Tai3 and Y.-S. Chen1,2
1) Section of Infectious Diseases, Department of Medicine, Kaohsiung Vet-
erans General Hospital, Kaohsiung City, Taiwan, 2) National Yang-Ming
University, Taipei, Taiwan, Republic of China and 3) Institute of Biomedical
Sciences, National Sun Yat-Sen University, Kaohisung, Taiwan, Republic of
China
Abstract
Meningitis is associated with an imbalance between matrix metal-
loproteinases (MMPs) and endogenous tissue inhibitors of MMP
(TIMPs). Serum and CSF were collected prospectively from all
patients with meningitis between January 2008 and December
2008 to measure the concentrations of MMP/TIMP in those
patients who underwent a lumbar puncture for a presumptive
diagnosis of meningitis. A total of 199 patients were enrolled
into the study. The concentrations of CSF MMP-9 and TIMP-1
were significantly higher in the meningitis group compared with
the control group (p 0.032 and p <0.001, respectively). How-
ever, the CSF TIMP-4 levels were significantly lower in the men-
ingitis groups compared with the control groups (p <0.001).
Patients with bacterial meningitis had higher CSF MMP-9 and
TIMP-1 levels than those who had aseptic meningitis and con-
trols. Patients with various infectious meningitis etiologies
tended to have higher CSF MMP-9 expression by gelatin zymog-
raphy when compared with the controls. In conclusion, MMP/
TIMP system dysregulation was found in patients with meningitis,
and CSF MMP and TIMP might act as novel indicators in patients
with meningitis.
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Meningitis is the most common serious infection of the cen-
tral nervous system (CNS). The case mortality rate is rela-
tively high and survivors may suffer from long-term, severe
neurological sequelae [1–4]. In bacterial meningitis, acute
breakdown of the blood–brain barrier (BBB) and accumula-
tion of blood-derived leukocytes in the cerebrospinal fluid
(CSF) lead to brain edema, cerebral vasculitis and ultimately
neuronal injury [5]. One of the prototypical destructive
events in the human brain, initiated by the release of inflam-
matory cytokines and ending with tissue destruction, is the
production of matrix metalloproteinases (MMPs) [5].
The MMPs constitute a family of zinc-binding endopeptid-
ases characterized by their ability to degrade various extra-
cellular matrixes [6]. The activity of MMP is highly regulated
both at the level of gene expression and by conversion of
latent pro-MMP to active enzymes [7]. Infectious meningitis
is associated with an imbalance between MMPs and endoge-
nous tissue inhibitors of MMP (TIMPs) [8,9]. In the extracel-
lular milieu, the activity of these enzymes is controlled by
four natural TIMPs. Changes in the fine balance between
MMPs and their tissue inhibitors drives extracellular matrix
turnover and may be associated with inflammation and neu-
rotoxicity [10]. The manner in which the matrix-degrading
enzymes and their TIMP inhibitors are regulated in the
microenvironment of the brain of humans with meningitis is
not well understood. This study was designed to obtain clues
concerning the potential roles of MMPs/TIMPs in patients
with meningitis.
Eligible subjects were enrolled into a prospective clinical
cohort of patients with suspected meningitis in the Depart-
ment of Infectious Diseases at Kaohsiung Veterans General
Hospital between January 2008 and December 2008. The
diagnosis of bacterial meningitis was based on detection of
the pathogen in the CSF by gram staining, bacterial culture
or antigen testing, and the presence of CSF pleocytosis [11].
Tuberculous (TB) meningitis was established on the basis of
the presence of symptoms and/or signs suggestive of menin-
gitis plus one of the following criteria: (i) positive culture of
M. tuberculosis, positive smear for acid-fast bacilli (AFB), or
positive polymerase chain reaction (PCR) from the CSF; (ii)
positive culture of M. tuberculosis, positive smear for AFB, or
positive PCR from other body fluids or organs; and (iii) nega-
tive CSF culture for virus, bacteria and fungi, plus clinical
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response to anti-tuberculosis therapy [12]. Cryptococcal
meningitis was diagnosed based on a positive CSF India ink
staining or a positive culture for the organism or a positive
cryptococcal antigen latex agglutination test [13]. Aseptic
meningitis was defined as patients with a positive CSF viral
culture or pleocytosis in the CSF with negative CSF bacterio-
logical studies, or pleocytosis in the CSF with viral isolation
from other sources such as a throat or a rectal swab [14].
A human immunodeficiency virus (HIV)-infected patient with
neurosyphilis was defined as having a positive HIV Western
blot test and a reactive serum rapid plasma reagin (RPR), as
well as a CSF white blood cell count 320 cells/uL or a reac-
tive CSF Venereal Disease Research Laboratory (VDRL) [15].
Lumbar punctures were performed if patients had neuro-
logical or ophthalmological symptoms/signs, change in con-
sciousness, ataxia, fever and/or meningeal sign. The CSF
control group (n = 111) consisted of patients with headache
or disturbed consciousness who underwent a lumbar punc-
ture for exclusion of tumour, subarachnoidal haemorrhage,
inflammatory disease or meningitis. The CSF samples were
centrifuged and the supernatants were frozen at )80C until
assayed. The study protocol, including informed consent, was
approved by the Institutional Review Board of the Kaohsiung
Veterans General Hospital.
Concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2 and
TIMP-4 in serum and CSF were determined using ELISA Kits
(R & D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions [9]. Activity of MMPs was analy-
sed by a modified sodium dodecyl sulfate–polyacrylamide gel
electrophoresis [9].
All of the data were expressed as mean ± standard devia-
tion. Concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2 and
TIMP-4 in CSF and serum in patients with meningitis and
controls were compared by Student t-test or Mann–Whitney
U-test. The mean concentrations of MMP-2, MMP-9, TIMP-1,
TIMP-2 and TIMP-4 in CSF for the different meningitis aetiol-
ogies were compared by one-way analysis of variance fol-
lowed by the Scheffe’s multiple range test. A Pearson
correlation test was used to compare the levels of CSF
parameters and concentrations of MMPs/TIMPs. The results
were presented as the mean ± SD. A p value <0.05 was con-
sidered statistically significant.
Between January 2008 and December 2008, a total of 199
patients with suspected meningitis were enrolled into this
prospective study, and the concentrations of MMP/TIMP in
the cerebrospinal fluid (CSF) and serum were measured. The
mean ages (y/o) of the meningitis and control groups were
not different (52.2 ± 20.2 (range 16–87) and 63.3 ± 19.6
(range 20–96), respectively). Most of them were men (67.4%
vs. 67%). Twenty-five patients had bacterial meningitis,
11 had TB meningitis, 11 had cryptococcal meningitis, 35 had
aseptic meningitis, and six patients had HIV and neurosyphi-
lis. For those 25 patients with bacterial meningitis, 20
patients had a definite aetiological diagnosis, and in the other
five the diagnosis was based on the presence of bacteria on
Gram’s stain of the CSF. Causal pathogens included Klebsiella
pneumoniae in seven, Streptococcus pneumoniae in three, Liste-
ria monocytogenes in two, and one each of Streptococcus saliva-
rius, Streptococcus pyrogenes, Streptococcus agalactiae,
Enterococcus, Pseudomonas aeruginosa, E. coli, Acinetobacter bau-
mannii and Staphylococcus aureus. The control group con-
sisted of 111 patients without meningitis, presenting with
headache or disturbance of consciousness, and who under-
went a diagnostic lumbar puncture. The diagnosis in the con-
trol group included septic shock in 52, metabolic
encephalopathy in 32, Guillain–Barre´ syndrome and vasculitis
in seven, stroke in five, infective endocarditis in four, malig-
nancy in four and HIV infection in four. Three patients had
herpes zoster infection.
The CSF concentrations of MMP-9 and TIMP-1 were sig-
nificantly higher in the patients with meningitis compared
with the controls. The CSF concentrations of TIMP-4 were
significantly lower in the patients with meningitis compared
with the controls (p <0.0001) (Table 1). Serum concentra-
tions of MMPs and TIMPs were not significantly different
between patients with meningitis and the controls. Further
subgroup analysis found significant differences in the concen-
trations of MMP-9 and TIMP-1 between patients with bacte-
rial meningitis and those who had aseptic meningitis and
controls. Patients with bacterial meningitis tended to have
higher CSF MMP-9 and TIMP-1 levels compared with other
meningitis aetiologies and controls Table 1.
We examined the correlation of CSF white cell count
with MMP-9 concentrations in patients with infectious men-
ingitis. Levels of MMP-9 in the CSF of patients significantly
correlated with the levels of CSF protein (r = 0.257,
p 0.001), CSF white cell count (r = 0.358, p <0.001), CSF
MMP-2 (r = 0.671, p <0.001), CSF TIMP-1 (r = 0.311,
p <0.001) and CSF TIMP-2 (r = 0.256, p <0.001) (Table 2).
The higher the white cell count level in the CSF of patients,
the higher the MMP-9 concentrations in the CSF. Levels of
CSF TIMP-4 were negatively associated with the concentra-
tions of CSF protein (r = )0.167, p 0.041) and CSF TIMP-1
(r = )0.229, p 0.003). We also found a strong correlation
between CSF protein and concentrations of CSF MMP-2 and
9 and TIMP-1, 2 and 4. The CSF white cell count was corre-
lated with levels of CSF MMP-2 and 9, and TIMP-1 and 2,
but not with TIMP-4 Table 2.
The CSF specimens from five of the patients and one of
the controls were randomly selected for analysis by gelatin
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zymography. All CSF specimens from patients and controls
demonstrated a band with a molecular mass of 72 kD
(MMP-2). However, only CSF specimens from patients with
infectious meningitis showed MMP-9 activity with a band
with a molecular mass of 92 kD.
MMP-9 in the CSF has been proposed as a marker of
meningitis, neurotropic viruses and neuroinflammation
[8,9,16]. MMP-9 has the capacity to degrade endothelial
basement membrane components, and is of strategic impor-
tance in the migratory processes into the CNS [17]. Elevated
concentrations of MMP-9 have been reported to alter the
blood-brain barrier, leading to brain barrier damage, neuroin-
flammatory processes and meningeal oedema [5,8,9].
The brain appears to be the source of the elevated MMP-
9 in the CSF of patients with meningitis. This hypothesis is
based on our findings that the serum concentrations of
MMP-9 in patients with infectious meningitis did not differ
from non-meningitis controls. There is evidence that MMP-9
is produced by infiltrating immune cells, ependimocytes, mi-
croglia [18,19] and other parenchymal or endothelial cells
[20]. Animal models and clinical studies of bacterial meningi-
tis also suggested degranulation of polymorphic leukocytes
(PMNs) as the primary source of CSF MMP-9 [8,20,21].
Conflicting results have been reported with regard to the
relationship between CSF pleocytosis and MMP-9 levels. A
relationship between increased MMP-9 levels in CSF and
the number of leukocytes in various neurological disorders
was first reported by Gijbels and others [22]. In contrast,
Paemen and others [16] studied inflammatory neurological
diseases such as optical neuritis and multiple sclerosis and
did not find a significant correlation of MMP-9 with CSF leu-
kocyte counts. In this study, a highly significant correlation
was found between CSF MMP-9 concentrations and CSF
leukocyte counts and protein. It is likely that increased con-
centrations of MMP-9 in CSF were derived from the transmi-
grating leukocyte cells because of damage to the blood-brain
barrier (BBB). These results suggest that increased MMP-9
levels are associated with BBB dysfunction and are depen-
dent on CSF pleocytosis. A significant increase in CNS con-
centrations of TIMP-1 has been observed in infectious
meningitis [8,9]. Increased expression of MMP-9 and TIMP-1
in CSF of bacterial meningitis, viral meningoencephalitis and
eosinophilic meningitis has also been reported by several
groups [8,9,20,23]. The finding that concentrations of TIMP-
1 were ten to hundreds-fold higher than MMP-9 in patients
with viral [23] and eosinophilic meningitis [9] and in our
patients, suggests that MMP-9 is bound to TIMP-1 [24]. In a
mouse brain experimental autoimmune encephalomyelitis
(EAE) model, Pagenstecher et al. [25] showed that upregula-
tion of MMP-9 was associated with marked enhancement ofT
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TIMP-1 expression. They found that TIMP-1 RNA is synthe-
sized by astrocytes ringing MMP-elaborating inflammatory
lesions. This suggests that TIMP-1 might function to contain
further the MMP-mediated expansion of the inflammatory
lesion by inhibiting tissue destruction caused by leukocyte
migration [25].
Upregulation of MMP-2 in meningitis has not been
reported [24]. Lee and others [26] showed that the persis-
tent increase of MMP-2 concentrations in patients with
tuberculous meningitis was associated with development of
complications. Patients with late neurological complications
had higher MMP-2 concentrations than those without neuro-
logical complications. In the current study, we did not find
higher CSF MMP-2 concentrations in patients with meningitis
in comparison with controls. Thus MMP-2 does not appear
to play an important role in patients with meningitis.
Expression of TIMP-2 is mainly constitutive [27]. In our
study, we did not find any significant differences in the levels
of CSF TIMP-2 between patients with meningitis and con-
trols. TIMP-2 is both an activator and an inhibitor of MMP-2
at lower and higher concentrations, respectively. TIMP-2
functions in connection with MT1-MMP to activate MMP-2
[28]. It is possible that either TIMP-2 does not play a major
role in meningitis or selective sampling time points failed to
reflect changes in MMP-2 or TIMP-2 expression in the CSF,
because they are measured in specimens from patients begin-
ning on the day they were hospitalized.
We found that the TIMP-4 concentration in CSF was sub-
stantially downregulated during the acute phase of meningitis.
This change may be caused by alteration of the cytokine
milieu and other biological factors that are major modulators
of TIMP expression [29] and may reflect greater roles of
these proteins in meningitis. The detailed mechanism for this
process is still unknown.
There were limitations to our study. Our sample size for
different meningitis aetiologies was relatively small. The sam-
pling time was different because specimens were collected at
the beginning of admission and patients were in different
stages of illness. Also, we did not measure the serum/CSF
albumin index. Although there were no significant differences
in the serum concentrations of MMPs and TIMPs between
patients with infectious meningitis and the controls, the pos-
sibility of MMP/TIMP accumulation in the CSF caused by pas-
sive influx instead of intrathecal production cannot be
completely excluded.
In conclusion, we found that the MMP/TIMP system was
dysregulated in patients with meningitis regardless of the
aetiology of meningitis. Patients with bacterial meningitis
tended to have higher CSF MMP-9 and TIMP-1 expression
compared with controls and meningitis due to other
causes.
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